| Catalog No. |
TD-HY377026 |
| Species reactivity |
Human |
| Applications |
Research Grade Biosimilar |
| Host species |
Humanized |
| Isotype |
IgG1 |
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
Equilibrative nitrobenzylmercaptopurine riboside-insensitive nucleoside transporter, 36 kDa nucleolar protein HNP36, ENT2, Equilibrative nucleoside transporter 2, SLC29A2, Hydrophobic nucleolar protein, 36 kDa, Equilibrative NBMPR-insensitive nucleoside transporter, Nucleoside transporter, ei-type, Delayed-early response protein 12, Solute carrier family 29 member 2, HNP36, DER12 |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G, purified from cell culture supernatant. |
| Accession |
Q14542 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS,pH7.4. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names |
VAL-1221,CAS:2145123-44-8 |
| Background |
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research. |
| Note |
For research use only. Not for use in clinical or therapeutic applications. |